BlackRock Health Sciences Term Trust (BMEZ) To Go Ex-Dividend on December 16th

BlackRock Health Sciences Term Trust (NYSE:BMEZ) announced a monthly dividend on Friday, December 6th,NASDAQ Dividends reports. Investors of record on Monday, December 16th will be given a dividend of 0.1781 per share on Monday, December 23rd. This represents a $2.14 annualized dividend and a dividend yield of 13.81%. The ex-dividend date of this dividend is Monday, December 16th.

BlackRock Health Sciences Term Trust has increased its dividend by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Price Performance

BMEZ stock traded down 0.02 on Friday, reaching 15.48. The company had a trading volume of 360,200 shares, compared to its average volume of 277,112. The company’s fifty day moving average is 15.61 and its 200 day moving average is 15.62. BlackRock Health Sciences Term Trust has a 1 year low of 14.38 and a 1 year high of 16.59.

Insider Transactions at BlackRock Health Sciences Term Trust

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 15,455 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was purchased at an average price of 16.14 per share, with a total value of 249,443.70. Following the transaction, the insider now owns 20,601,568 shares in the company, valued at 332,509,307.52. This trade represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 99,630 shares of company stock worth $1,585,113 in the last three months.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.